The first US biosimilar - Zarxio from Sandoz - has been cleared for market. But the judges say it wasn't an easy decision.

After 28 years of R&D at GSK, the world has its first malaria vaccine.

A new mathematical model aims to improve drugs for cancer, viruses and bacteria.

A round-up of the latest expansion plans and new facilities as building fever grips the industry

Could existing drugs be repurposed as a shortcut to treating Ebola?

Big pharma is turning to outside sources to fill pipelines, but how often are companies backing the wrong horse?

Manufacturers must prove that new drug products are free of cancer-causing impurities

How did the NIH get it so wrong – and how can it move on?

Is pharma keeping up with the latest innovations? US legislators say no, and are looking to a new act to accelerate approvals.

How much do the public really know about pharma R&D?